- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Supriya Lifescience reported strong Q2 performance with revenue up 20.3% YoY to 199.83 Cr and PAT rising 9.3% to 50.43 Cr. For the half-year, revenue grew 5.6% to 344.91 Cr, though PAT saw a slight dip of 6.1% to 85.22 Cr, reflecting some margin pressure. Europe and Asia continue as key regional growth drivers.
The company's strategy is centered on robust R&D, with two new labs developing 3-4 APIs annually and managing product lifecycles. Backward integration already covers 78% of H1 revenue, ensuring supply security. Recently, a state-of-the-art Module E block boosted capacity by 55% to 932 KLPD, and a new Finished Dosage Form (FDF) facility is set to commission in H2 FY26.
Future growth is fueled by a significant 10-year exclusive API supplier contract with a leading European company, expected to generate 60 Cr/year from FY27. Supriya is also expanding globally to new markets like North America, Japan, and Australia, while venturing into new therapeutic areas like anti-diabetics and anesthetics.